The pharmaceutical company Bayer billed 787 million euros in 2025 in Spain. The figure represents a drop of 4% compared to the previous year, in which the firm achieved sales of 822 million. As explained by the CEO of the Bayer subsidiary in Spain, Jordi Sánchez, the drop in billing is mainly due to the withdrawal from the market of the insecticide Movento, which has been banned in Europe. This impact has been particularly noticeable in the sales of the company's agricultural division –the Crop Science area–, which has reduced sales by 20%, to 227 million euros.

The Catalan pharmaceutical company Rubió has invested 14 million euros in the expansion of its production plant in Castellbisbal (Vallès Occidental). The expansion will double the current production capacity of approximately 10 million units to 20 million units, the company reported.

Peace at Grifols. One of the funds critical of the Catalan multinational's management, Mason Capital, which holds a 3.174% stake, has announced its support for the group's management and the proposed candidates and changes to the board of directors.

The biopharmaceutical multinational Sanofi announced this Tuesday the creation of a hub innovation center in Barcelona, ​​​​in the 22@ technology district, with 300 "high-talent" jobs and which will be fully operational by the end of this year. This was announced by the general manager of Sanofi Iberia, Raquel Tapia, during the inauguration of the Science Lab, a traveling interactive exhibition that brings science, immunology and innovation closer to the public and which can be seen until April 26 at the Moll de la Barceloneta.